Earnings summaries and quarterly performance for Xeris Biopharma Holdings.
Executive leadership at Xeris Biopharma Holdings.
Board of directors at Xeris Biopharma Holdings.
Research analysts who have asked questions during Xeris Biopharma Holdings earnings calls.
Chase Knickerbocker
Craig-Hallum Capital Group
4 questions for XERS
Also covers: AVDL, BFLY, BVS +17 more
David Amsellem
Piper Sandler Companies
3 questions for XERS
Also covers: ABBV, ALKS, AMGN +27 more
JD
Jason Dorr
Oppenheimer & Co. Inc.
2 questions for XERS
Also covers: TRVI
LG
Leland Gershell
Oppenheimer & Co. Inc.
2 questions for XERS
Also covers: ARGX, ASND, CAPR +13 more
Mazahir Alimohamed
Leerink Partners
2 questions for XERS
Also covers: AKBA, AMRN, AQST +2 more
OL
Oren Livnat
H.C. Wainwright
2 questions for XERS
Also covers: ANIP, AVDL, CARA +7 more
AR
Alex Riesemann
Piper Sandler Companies
1 question for XERS
Also covers: OGN, SUPN
Christian Clark
Leerink Partners
1 question for XERS
Also covers: SCPH
GS
Glen Santangelo
Jefferies
1 question for XERS
Also covers: ALGN, ANIP, BHC +12 more
Recent press releases and 8-K filings for XERS.
Xeris Biopharma Holdings, Inc. Announces Preliminary Record Q4 and Full-Year 2025 Revenue
XERS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Xeris Biopharma Holdings, Inc. expects record total revenue for full-year 2025 of $292 million, surpassing its guidance range of $285-$290 million and reflecting 44% growth compared to the prior year.
- Recorlev® net revenue is anticipated to be $45 million for the fourth quarter 2025 and $139 million for the full-year 2025.
- The company delivered positive Adjusted EBITDA in every quarter of 2025.
Jan 8, 2026, 12:18 PM
Xeris anticipates record 2025 revenue
XERS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Xeris Biopharma Holdings expects to report record full-year 2025 total revenue of $292 million, exceeding its guidance range of $285-$290 million and reflecting 44% growth compared to the prior year.
- The company anticipates Recorlev® net revenue of $139 million for the full year 2025 and $45 million for the fourth quarter.
- Xeris also reported Gvoke® revenue growth of over 13% compared to the prior year and achieved positive Adjusted EBITDA in every quarter of 2025.
- Full-year 2025 financial results and the 2026 outlook are planned for release on March 2, 2026.
Jan 8, 2026, 12:00 PM
Xeris Pharmaceuticals Updates Guidance and Details Growth Strategy
XERS
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Xeris Pharmaceuticals (XERS) has raised its full-year guidance to $285 million-$290 million, representing 42% growth at the midpoint, and achieved net income for the first time last quarter.
- The company's growth driver, Recorlev, is projected to be a billion-dollar brand by 2035 and is supported by patents extending to 2040 and orphan exclusivity until 2028.
- To accelerate Recorlev's growth, Xeris expanded its sales force by 50% in August 2024 and plans to double it again by January 2025, aiming to target 12,000 physicians.
- Xeris is developing XP-8121, a once-weekly injectable levothyroxine, which targets a $1 billion-$3 billion market opportunity for 3-5 million patients, with a Phase 3 trial launching in H2 2026.
- The company has laid out a target of $750 million in revenue by 2030 from its existing product portfolio.
Dec 2, 2025, 5:30 PM
Xeris Provides Business Update at Piper Sandler Healthcare Conference
XERS
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Xeris reported strong financial performance, raising its guidance to $285 million-$290 million for 42% growth at the midpoint, and achieved net income for the first time last quarter.
- The company is significantly expanding its commercial footprint for its growth engine, Recorlev, by doubling its sales force to target 12,000 physicians starting January 1st.
- Recorlev is protected by four Orange Book-listed patents extending to 2040 and orphan exclusivity until 2028, supporting its projection as a billion-dollar brand by 2035.
- Xeris's pipeline product, XP-8121, a once-weekly levothyroxine injection, targets a $1 billion-$3 billion market opportunity and is slated to begin a 1,000-patient Phase 3 trial in late H2 2026.
Dec 2, 2025, 5:30 PM
Xeris Biopharma Holdings Announces Patent Allowance for XP-8121
XERS
New Projects/Investments
Legal Proceedings
- Xeris Biopharma Holdings, Inc. announced a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its XP-8121 patent application on December 1, 2025.
- The allowed claims are specific to the XP-8121 formulation, an investigational, ready-to-use liquid designed for once-weekly subcutaneous injection to address hypothyroidism.
- This patent is considered a key milestone in strengthening the company's intellectual property protection around this Phase 3-ready pipeline program.
Dec 1, 2025, 12:00 PM
Xeris Biopharma Reports Record Q3 2025 Results and Raises Full-Year Revenue Guidance
XERS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Xeris Biopharma reported a record-setting Q3 2025, with total product revenue exceeding $74 million, representing a 40% increase year over year.
- The company raised the lower end of its full-year 2025 total revenue guidance to a range of $285-$290 million, which signifies a 42% increase at the midpoint compared to 2024.
- Recorlev revenue more than doubled year-over-year to $37 million in Q3 2025, driven by a 108% increase in patients on therapy.
- Xeris achieved net income for the first time in its history and reported adjusted EBITDA of $17.4 million for Q3 2025, with a gross margin of 85%.
- The company is making strategic investments in commercial expansion for Recorlev and advancing its XP-8121 pipeline, with the phase three clinical trial expected to start in the second half of 2026, while committing to remain adjusted EBITDA positive.
Nov 6, 2025, 1:30 PM
Xeris Biopharma Holdings, Inc. Announces Record Q3 2025 Financial Results and Updates Full-Year Guidance
XERS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Xeris Biopharma Holdings, Inc. reported record financial results for the third quarter ended September 30, 2025, with total product revenue increasing 40% year-over-year to $74 million.
- Recorlev revenue notably grew 109% year-over-year to $37 million in Q3 2025, driven by increased patient demand.
- The company achieved a net income of $0.6 million for Q3 2025, a significant improvement from a net loss of $15.7 million in the same period last year.
- Xeris updated its full-year 2025 total revenue guidance to $285-$290 million, which implies 42% growth at the midpoint compared to last year.
Nov 6, 2025, 12:43 PM
Beta Bionics Reports Q3 2025 Financial Results and Raises Full Year Guidance
XERS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Beta Bionics reported net sales of $27.3 million for the third quarter of 2025, representing a 63% increase compared to the third quarter of 2024.
- The company's net loss for Q3 2025 was $14.2 million.
- As of September 30, 2025, Beta Bionics had $274.0 million in cash, cash equivalents, short-term investments, and long-term investments.
- Beta Bionics raised its full-year 2025 total revenue guidance to greater than $96.5 million (previously $88 million to $93 million) and its estimated gross margin to 54% to 55% (previously 52% to 55%).
Oct 28, 2025, 8:02 PM
Quarterly earnings call transcripts for Xeris Biopharma Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more